Literature DB >> 12184712

Personal health care and the new media in anticoagulant treatment.

Heikki Lamminen1, Samuli Niiranen, Kirsi Niemi, Heikki Mattila, Seppo Kalli.   

Abstract

OBJECTIVE: To determine the feasibility of a more personal anticoagulant treatment follow-up routine involving the use of a personal measurement device along with the new media (e.g. the Internet).
DESIGN: A telephone interview.
SETTING: The municipality of Ikaalinen with a total population of 7795.
SUBJECTS: Forty patients on anticoagulant treatment who have personal responsibility for their treatment follow-up. MAIN OUTCOME MEASURES: Demographic data, data and opinions on anticoagulant treatment and data and opinions on personal health care and the new media.
RESULTS: More than two-thirds of the interviewed were generally pleased with the current AC treatment routine in the Ikaalinen area. Sixty-eight percent of the patients feel that they are able to determine the anticoagulant dosage from the follow-up test results and almost a third have independently changed their dosage. Approximately half of the interviewed were willing to take various health-related measurements at home, but approximately only 20% of the interviewed were ready to use health-related services; for example, related to the follow-up of anticoagulant treatment, through the new media.
CONCLUSION: Part of the population receiving anticoagulant treatment is ready to move to a more personal treatment routine involving home measurements in follow-up tests. However, most interviewed patients were not interested in using the new media as part of the new routine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12184712

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  1 in total

1.  Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland.

Authors:  Irma Virjo; Kari Mäkelä; Juhani Aho; Pentti Kalliola; Harri Kurunmäki; Leena Uusitalo; Markku Valli; Suvi Ylinen
Journal:  Scand J Prim Health Care       Date:  2010-09-07       Impact factor: 2.581

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.